Thymogen
Research OnlyAlso known as: Glu-Trp, EW dipeptide, Timogen, Glutamyl-Tryptophan, L-Glu-L-Trp
A synthetic dipeptide (glutamyl-tryptophan) developed in Russia as a defined successor to thymalin. Approved in Russia for immunomodulation with extensive Russian clinical literature. Represents an attempt to create a standardized, synthetic thymic peptide. Not approved by Western regulatory agencies.
Research Statistics
Russian bioregulator (Khavinson lab); synthetic thymic dipeptide (Glu-Trp) approved in Russia. Research primarily from Russian institutes. No independent Western clinical trials. Thymic dipeptide mechanism proposed but lacks Western validation.
Research Dossier
Overview
What is Thymogen and what does the research say?
Mechanism of Action
The proposed mechanisms of Thymogen are based on Russian clinical studies, animal research, and in vitro experiments. Western-standard mechanistic validation is lacking.
How It Works (Simplified)
Thymogen appears to act as an immunomodulatory signal through several pathways:
Activates T-cell differentiation and enhances T-cell recognition of peptide-MHC complexes, supporting adaptive immune function.
Modulates IL-2, IFN-gamma, TNF, and IL-6 production, potentially balancing pro- and anti-inflammatory responses.
Activates neutrophil chemotaxis and phagocytosis, enhancing the first-line immune defense against pathogens.
May interact with DNA promoter regions in lymphocytes, transforming heterochromatin to euchromatin and activating gene transcription.
Scientific Pathways
T-Cell Differentiation Pathway (Adaptive Immunity)
Thymogen → T-cell receptor signaling → MHC complex recognition enhancement
↓
T-lymphocyte differentiation & activationCytokine Modulation Pathway (Inflammation Control)
Thymogen → MAPK pathway modulation → Reduced TNF/IL-6 → Anti-inflammatory effect
↓
IL-2/IFN-gamma regulation → Balanced immune responseKey Research: Khavinson VKh et al. (Russia, 1997) demonstrated T-cell differentiation and cytokine modulation in clinical settings. PMID:9637345
Important Limitations
- Most clinical studies conducted in Russia with variable methodology
- Specific receptor for Thymogen not definitively identified
- Mechanism by which a rapidly-degraded dipeptide exerts lasting effects remains unclear
- Translation to Western clinical standards is unconfirmed
- Bioavailability and pharmacokinetics not fully characterized
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on Russian clinical reports: Initial immunomodulatory effects may begin. T-cell differentiation markers may start to normalize. Cytokine profile changes observed in some studies. No Western-standard pharmacokinetic data available.
Russian clinical protocols typically show continued immune parameter improvements. IL-2 and IFN-gamma modulation reported. Neutrophil function enhancement observed in some studies.
Extended treatment courses in Russian protocols suggest sustained immunomodulatory effects. Secondary immunodeficiency markers reportedly normalize in majority of patients in Russian studies.
Long-term data comes primarily from Russian observational studies. Duration of effect after discontinuation not well characterized. Optimal treatment length remains undefined by Western standards.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Thymogen product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Thymogen with other peptides. Based on published research and mechanistic considerations.
Thymalin
SynergisticThymogen is derived from thymalin research. Both modulate thymic immune pathways. Concurrent use may have overlapping effects on T-cell differentiation. No direct studies on combination.
Thymosin-Alpha-1
CompatibleBoth are thymic-derived immunomodulators with complementary mechanisms. Thymosin Alpha-1 has broader regulatory approval and more Western clinical data. No known contraindications to combination.
Thymulin
CompatibleDifferent thymic peptides with overlapping immunomodulatory goals. Thymulin requires zinc as cofactor while Thymogen does not. Theoretical complementary effects on T-cell function.
BPC-157
CompatibleNon-overlapping mechanisms. Thymogen modulates immune function while BPC-157 promotes tissue repair. May provide complementary benefits in recovery contexts.
LL-37
CompatibleLL-37's antimicrobial and immunomodulatory properties may complement Thymogen's T-cell modulation. Both affect immune function through different pathways.
Epithalon
CompatibleBoth are Russian-developed peptides from Khavinson research. Epithalon targets telomerase while Thymogen targets immune function. Theoretical synergy in anti-aging protocols.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Thymogen
Thymogen Calculators
Related Peptides
Alpha-Defensins
HNP-1, HNP-2, HNP-3 +5 more
A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
KPV
Lys-Pro-Val, Lysine-Proline-Valine, alpha-MSH(11-13) +1 more
A naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical studies demonstrate potent anti-inflammatory effects via NF-kB inhibition, but no human clinical trials have been conducted. Research has focused on inflammatory bowel disease and skin inflammation models.
Kristagen
EDG, Glu-Asp-Gly, Immune tripeptide
A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Lactoferricin
LFcinB, Lactoferricin B, LfcinB +1 more
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
LL-37
Cathelicidin, hCAP18, Human Cationic Antimicrobial Peptide 18 +3 more
The only human cathelicidin antimicrobial peptide, discovered at Karolinska Institute in Sweden (1995). A 37-amino acid peptide with broad-spectrum antimicrobial activity and immunomodulatory functions. Extensive mechanistic research supports roles in innate immunity, wound healing, and host defense.
Murepavadin
POL7080, RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.